IMF lowers growth forecast to 3.5pc Reverting to cost-plus structure not the answer IMF, World Bank meetings: Aurangzeb leads ...

BALANGIR: A day after the video of Titilagarh BJP MLA Nabin Kumar Jain engaging in celebratory fire during a Ram Navami ...

Melinda Gooderham, MD, MSc, FRCPC, discusses findings from the Latitude PsO 3001 and Latitude PsO 3002 studies evaluating zasocitinib. This content was developed independently and is not endorsed by ...

HealthDay News — Once-daily oral zasocitinib (TAK-279), an oral tyrosine kinase 2 (TYK2) inhibitor, provides a durable response in adults with moderate-to-severe plaque psoriasis (PsO), according to a ...

Adding tirzepatide to ixekizumab significantly improved primary and key secondary outcomes ...

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

Once-daily oral zasocitinib for moderate to severe plaque psoriasis demonstrated rapid and durable skin clearance and a consistent safety profile, according to data presented at the American Academy ...

71.4% and 69.2% of patients treated with zasocitinib achieved a static Physician Global Assessment (sPGA) score of 0/1 versus placebo (10.7% and 12.6%) and apremilast (32.1% and 29.7%) at week 16 (p<0 ...

Takeda Pharmaceutical (NYSE:TAK) highlighted late-breaking Phase III data for investigational TYK2 inhibitor zasocitinib in ...

Mar 28, 2026-- Takeda ( TSE:4502/NYSE:TAK ) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279 ...

PROSPERIDAD, Agusan del Sur — Governor Santiago Cane Jr. has announced a P1 million reward for homegrown athletes who break national records during the Palarong Pambansa 2026 set from May 24 to 31 in ...